About Putative inactive group IIC secretory phospholipase A2
Putative inactive group IIC secretory phospholipase A2 (PLA2G2C) is a protein
from Homo sapiens identified by UniProt accession
Q5R387, 149 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | Putative inactive group IIC secretory phospholipase A2 |
|---|
| UniProt accession | Q5R387 |
|---|
| Gene | PLA2G2C |
|---|
| Organism | Homo sapiens |
|---|
| Length | 149 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (68)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.24
- azoospermia · score 0.09
- Male infertility with spermatogenesis disorder due to single gene mutation · score 0.07
- Female infertility due to fertilization defect · score 0.07
- Rare genetic female infertility · score 0.07
- partial chromosome Y deletion · score 0.07
- male infertility with teratozoospermia due to single gene mutation · score 0.07
- spermatogenic failure 3 · score 0.06
- spermatogenic failure 55 · score 0.06
- spermatogenic failure 26 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5R387-F1 | alphafold | PREDICTED | 72.10 | — |
Amino-acid sequence (149 residues)
MKVIAILTLL LFCSPTHSSF WQFQRRVKHI TGRSAFFSYY GYGCYCGLGD KGIPVDDTDR HSPSSPSPYE KLKEFSCQPV LNSYQFHIVN GAVVCGCTLG PGASCHCRLK ACECDKQSVH CFKESLPTYE KNFKQFSSQP RCGRHKPWC
Explore Putative inactive group IIC secretory phospholipase A2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets